Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six‐year cohort analysis

Patients undergoing allogeneic stem cell transplantation (aSCT) are at high risk to develop an invasive fungal disease (IFD). Optimisation of antifungal prophylaxis strategies may improve patient outcomes and reduce treatment costs.

[1]  D. Liew,et al.  A population‐based analysis of attributable hospitalisation costs of invasive fungal diseases in haematological malignancy patients using data linkage of state‐wide registry and costing databases: 2009‐2015 , 2019, Mycoses.

[2]  D. Seidel,et al.  Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016. , 2019, The Journal of hospital infection.

[3]  U. Holtick,et al.  Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation , 2018, Bone Marrow Transplantation.

[4]  D. Seidel,et al.  FungiScope™—Global Emerging Fungal Infection Registry , 2017, Mycoses.

[5]  D. Denning,et al.  An estimation of burden of serious fungal infections in France. , 2016, Journal de mycologie medicale.

[6]  C. Scheid,et al.  A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. , 2016, The Journal of antimicrobial chemotherapy.

[7]  M. Hoenigl,et al.  Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels , 2016, Antimicrobial Agents and Chemotherapy.

[8]  G. Papanicolaou,et al.  Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Vehreschild,et al.  A cost and resource utilization analysis of micafungin bridging for hemato‐oncological high‐risk patients undergoing allogeneic stem cell transplantation , 2015, European journal of haematology.

[10]  M. Vehreschild,et al.  Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato‐oncological high‐risk patients: a web‐based non‐interventional trial in four large university hospitals in Germany , 2014, Transplant infectious disease : an official journal of the Transplantation Society.

[11]  A. Shimabukuro-Vornhagen,et al.  Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: A 6‐yr analysis from the cologne cohort for neutropenic patients , 2014, European journal of haematology.

[12]  J. Glossmann,et al.  Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[13]  M. von Bergwelt-Baildon,et al.  Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  M. Kiehl,et al.  Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals , 2012, Mycoses.

[15]  N. Mahlaoui,et al.  Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. , 2012, Journal of Antimicrobial Chemotherapy.

[16]  C. Heussel,et al.  Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation , 2011, British journal of haematology.

[17]  J. Dipersio,et al.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. , 2010, Blood.

[18]  E. Dodds-Ashley.  Management of Drug and Food Interactions with Azole Antifungal Agents in Transplant Recipients , 2010, Pharmacotherapy.

[19]  J. Perfect,et al.  Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[20]  E. Anaissie,et al.  Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Christian Weber,et al.  German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.